Mavyret
Phase 3Small molecule
Mavyret is one of 33 small molecule programs targeting Hepatitis C. It is currently in Phase 3.
1
Indications
5
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Hepatitis C
#DrugCompanyPhaseTrials
1Sovaldi
GileadApproved
Actos
TakedaApproved
Selzentry
GSKApproved
Neoral
NovartisApproved
Afinitor
NovartisApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Prograf
VVeloxis Pharmaceuticals
Approved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Suboxone
IIndivior Inc.
Approved
Retrovir
BBp Consulting, Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatitis C4 trials
Show 1 more trial
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
Completed·—·N/A·NCT05108935·17 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mavyret. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- MMassachusetts General Hospital